Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct thrombin inhibitors vs low molecular weight heparin in Staphylococcus aureus bacteraemia
2012-004863-29Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Staphylococcal bacteremia and venous thromboembolism (VTE) comparing Dabigatran prophylaxis, Argatroban prophylaxis and Enoxaparin prophylaxis (3 arms). Primary endpoint: Safety of dabigatran/argatroban versus enoxaparin. Started Jan 2013; status: completed.
02
Drugs
dabigatranargatrobanenoxaparin
03
Conditions
Staphylococcal bacteremiavenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2012-004863-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004863-29.